0
0
Read Time:6 Minute, 39 Second
NEW DELHI — In a comprehensive set of reports presented to Parliament, a influential oversight committee has issued a sweeping blueprint to reform India’s fragmented cancer care system. Addressing critical vulnerabilities ranging from staggering out-of-pocket medical costs to severe infrastructure bottlenecks, the Parliamentary Standing Committee on Health and Family Welfare has called for urgent structural interventions, including tax overhauls, dynamic health insurance rates, and aggressive expansion of preventive screening at the grassroots level.
The findings—detailed across the committee’s 175th, 176th, and 177th reports released on August 7, 2026—highlight a growing public health crisis. With cancer care in India remaining intensely capital-intensive and geographically concentrated, millions of families are pushed into severe financial hardship every year trying to secure life-saving treatments.
The Financial Strain of Fighting Cancer
Cancer care requires immense capital outlay. According to the Parliamentary Committee, establishing a state-of-the-art 500-bed specialized oncology hospital requires an initial investment of approximately ₹1,000 crore, alongside a four-year gestation period before operations begin. Furthermore, securing institutional land in urban centers creates a massive financial hurdle, with land costs in regions like the National Capital Region (NCR) ranging between ₹50 crore and ₹250 crore for a five-acre plot.
Because healthcare facilities lack “priority-sector lending” status from financial institutions, hospital developers are frequently forced to rely on high-cost commercial loans or private equity financing. These high capital costs are inevitably passed down to patients.
“When capital costs and land acquisition are left to market forces without regulatory relief, tertiary healthcare becomes prohibitively expensive,” notes Dr. Rajesh Verma, a Delhi-based health economics analyst not involved in the committee’s proceedings. “The financial engine of a hospital dictates its pricing structure. If a hospital borrows at commercial rates to buy land and import radiation equipment, patient billing is where that debt is serviced.”
Compounding this problem is the current tax structure. While healthcare services in India are exempt from the Goods and Services Tax (GST), this status paradoxically prevents tertiary hospitals from claiming Input Tax Credit (ITC) on capital investments. Medical equipment and specialized construction materials carry an 18% GST burden alongside heavy import duties, making advanced diagnostic and radiation equipment nearly 35% more expensive in India than in manufacturing hubs abroad.
To lower these barriers, the Parliamentary Panel recommended three major structural changes:
-
Zero-Rated GST Status: Reclassify healthcare services from “GST Exempt” to “Zero-Rated GST (0%).” This administrative shift would allow hospitals to claim Input Tax Credit on advanced machinery, consumables, and infrastructure, directly curbing operational costs.
-
Priority Sector Financing: Grant priority-sector lending status to specialized non-profit and tertiary oncology centers to enable access to low-interest institutional loans, alongside mandatory concessional land allotments by state governments.
-
Customs Rationalization: Reduce import duties on non-indigenously manufactured radiation technologies while expanding targeted incentives under the “Make in India” initiative to boost domestic manufacturing of diagnostic equipment.
Out-of-Pocket Crisis and Package Rate Disconnects
For the average Indian family, a cancer diagnosis brings immediate financial distress. The committee expressed grave concern over data showing that 70% to 80% of cancer treatment expenditure in India is paid directly out-of-pocket, with the average treatment cost reaching ₹7.5 lakh per patient.
+-------------------------------------------------------------------------+
| INDIAN CANCER CARE: CURRENT CHALLENGES |
+------------------------------------+------------------------------------+
| FINANCIAL BURDEN | INFRASTRUCTURE & TAXATION |
| • 70%-80% Out-of-Pocket Expense | • ₹1,000 Cr setup cost (500 beds) |
| • ₹7.5 Lakh average treatment cost | • 35% higher equipment cost via |
| • 50%-60% retail drug markups | GST (18%) & import duties |
+------------------------------------+------------------------------------+
While public insurance frameworks such as Ayushman Bharat (PM-JAY), the Central Government Health Scheme (CGHS), and ESIC exist to shield vulnerable populations, the empanelment of premier private oncology hospitals remains severely constrained. The panel discovered that government reimbursement rates are often up to 70% lower than prevailing market costs. Because these rates were fixed on basic marginal costing principles, they fail to account for capital depreciation, modern oncology protocols, or medical inflation—making participation financially unviable for many tertiary care providers.
The report also spotlighted pricing loopholes in pharmaceuticals and diagnostics. Despite price caps enforced under the Drug Price Control Order (DPCO), retail margins on anti-cancer medications remain excessively high at 50% to 60%. Drug manufacturers frequently circumvent price ceilings by introducing alternate dosage strengths or minor reformulations. Meanwhile, high-volume diagnostic procedures such as PET-CT scans, MRIs, and genetic profiling suffer from unstandardized, wildly fluctuating price points.
To address these gaps, the committee directed the Ministry of Health and Family Welfare, the National Health Authority (NHA), and the National Pharmaceutical Pricing Authority (NPPA) to execute systemic reforms:
-
Dynamic Package Rate Revision: Overhaul PM-JAY and CGHS reimbursement rates using inflation-indexed calculations that factor in modern treatment protocols and capital infrastructure depreciation.
-
Expansion of Price Controls: Expand the National List of Essential Medicines (NLEM) and DPCO coverage to include all alternate drug strengths, supportive care medications (such as anti-emetics and antifungal therapies), and strictly enforce Trade Margin Rationalization (TMR).
-
Diagnostic Price Ceilings: Establish nationwide ceiling prices for critical diagnostic imaging and genetic testing.
-
Universal Access to Patient Assistance Programmes (PAPs): Issue clear guidelines allowing patients enrolled in public health insurance schemes to simultaneously access manufacturer-funded drug assistance programs, from which they are currently excluded.
Expanding Public-Private Partnerships and Grassroots Screening
Mitigating the nation’s growing cancer burden requires moving beyond hospital-based tertiary care toward early detection and preventive medicine. Citing successful state-level interventions—such as Punjab’s model of delivering low-cost radio-diagnostics at CGHS-capped rates and Goa’s public-private dialysis partnerships—the committee advocated for a standardized national Public-Private Partnership (PPP) policy framework.
Under the proposed framework, state governments would provide land and basic infrastructure, while private or non-profit institutes manage clinical operations, mobile diagnostic units, and technical training. A portion of revenues generated would be reinvested to subsidize public health insurance and expand rural care.
+-------------------------------------------------------------------------+
| INTEGRATED CANCER SCREENING FRAMEWORK |
+-------------------------------------------------------------------------+
| |
| [ National PPP Framework ] ---> Provides Land & Basic Infrastructure |
| |
| [ ASHA & Anganwadi Workers ] -> Conduct Community Outreach & Identification|
| |
| [ Primary Health Centres ] ---> Mobile Diagnostic Units & Screening |
| (Oral, Cervical, Breast) |
| |
| [ National Vaccination ] ---> HPV Immunization Drive (Girls 9-26 yrs) |
| |
+-------------------------------------------------------------------------+
Crucially, the report emphasizes grassroots engagement. The panel recommended:
-
Mandatory Screening in PM-JAY: Explicitly incorporating comprehensive screening for oral, cervical, and breast cancers into the preventive benefits package of Ayushman Bharat.
-
Community-Level Deployment: Utilizing the vast network of Accredited Social Health Activists (ASHA) and Anganwadi workers to conduct community outreach, paired with regular mobile diagnostic camps at Primary Health Centres (PHCs) and Community Health Centres (CHCs).
-
National HPV Immunization: Launching a nationwide human papillomavirus (HPV) vaccination campaign targeting girls aged 9 to 26 years to prevent cervical cancer—one of the leading causes of cancer mortality among Indian women.
The Road Ahead
Public health experts have largely welcomed the parliamentary panel’s recommendations, noting that treating cancer as both an economic and a clinical challenge is long overdue. However, implementation will require tight coordination between central ministries, state health departments, and private stakeholders.
If translated into policy, zero-rating GST for healthcare, rationalizing diagnostic pricing, and institutionalizing early screening could fundamentally shift India’s cancer trajectory—turning a historically catastrophic diagnosis into a manageable, treatable condition for millions.
References & Data Sources
-
Parliamentary Standing Committee on Health and Family Welfare: 175th, 176th, and 177th Reports on Government-Private Collaboration and Cancer Care Infrastructure, Department-related Parliamentary Standing Committee, Parliament of India (Presented Aug 7, 2026).
-
Press Information Bureau (PIB) Delhi: Press Release on the 175th, 176th, and 177th Reports of the Parliamentary Standing Committee on Health & Family Welfare (Published Aug 7, 2026).
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
